These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28597168)

  • 1. Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p).
    Lacerda MP; Guedes NR; Yamakawa PE; Pereira AD; Fonseca ARBMD; Chauffaille MLLF; Goncalves MV; Yamamoto M; Rodrigues CA
    Ann Hematol; 2017 Sep; 96(9):1577-1578. PubMed ID: 28597168
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
    Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
    [No Abstract]   [Full Text] [Related]  

  • 3. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
    Wierda WG
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):214-216. PubMed ID: 31188811
    [No Abstract]   [Full Text] [Related]  

  • 4. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
    Gopalakrishnan S; Wierda W; Chyla B; Menon R; Miles D; Humerickhouse R; Awni W; Salem AH; Mensing S; Freise KJ
    Clin Pharmacol Ther; 2021 Feb; 109(2):424-432. PubMed ID: 32749675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world outcomes of venetoclax and rituximab for chronic lymphocytic leukemia/small lymphocytic lymphoma: A retrospective analysis of nine Japanese cases.
    Saburi M; Nishikawa T; Miyazaki Y; Kohno K; Sakata M; Okuhiro K; Nakayama T; Ohtsuka E; Ogata M
    J Clin Exp Hematop; 2024; 64(2):152-155. PubMed ID: 38925975
    [No Abstract]   [Full Text] [Related]  

  • 6. Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Okubo S; Ogawa N; Sakai M; Nishimura Y; Chyla B; Sun Y; Maruyama D
    Int J Hematol; 2023 Oct; 118(4):526-528. PubMed ID: 37581752
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.
    Milne K; Sturrock B; Chevassut T
    Curr Oncol Rep; 2020 Mar; 22(4):36. PubMed ID: 32172299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia.
    Rogers KA
    Lancet Oncol; 2024 Jun; 25(6):685-687. PubMed ID: 38821078
    [No Abstract]   [Full Text] [Related]  

  • 9. Pairing obinutuzumab with venetoclax in relapsed CLL.
    Rogers KA; Thompson PA
    Leuk Lymphoma; 2024 May; 65(5):543-545. PubMed ID: 38497550
    [No Abstract]   [Full Text] [Related]  

  • 10. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
    Stilgenbauer S; Tausch E; Roberts AW; Davids MS; Eichhorst B; Hallek M; Hillmen P; Schneider C; Schetelig J; Böttcher S; Kater AP; Jiang Y; Boyer M; Popovic R; Ghanim MT; Moran M; Sinai WJ; Wang X; Mukherjee N; Chyla B; Wierda WG; Seymour JF
    Blood Adv; 2024 Apr; 8(8):1992-2004. PubMed ID: 38290108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I manage CLL with venetoclax-based treatments.
    Wierda WG; Tambaro FP
    Blood; 2020 Apr; 135(17):1421-1427. PubMed ID: 32076705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation.
    Mohan V; Jain S; Naithani R
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31152. PubMed ID: 38953139
    [No Abstract]   [Full Text] [Related]  

  • 13. [Resistance mechanisms and treatment strategies of Venetoclax in chronic lymphocytic leukemia].
    Zou HS; Yi SH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):783-787. PubMed ID: 33113617
    [No Abstract]   [Full Text] [Related]  

  • 14. Upfront therapy: the case for continuous treatment.
    Tam CS
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):55-58. PubMed ID: 34889433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.
    Hampel PJ; Parikh SA; Call TG; Shah MV; Bennani NN; Al-Kali A; Rabe KG; Wang Y; Muchtar E; Leis JF; Kenderian SS; Koehler AB; Schwager SM; Slager SL; Kay NE; Hanson CA; Van Dyke DL; Shi M; Ding W
    Blood Cancer J; 2021 Mar; 11(3):47. PubMed ID: 33654067
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia.
    Yang L; Banerji V
    Lancet Oncol; 2024 Apr; 25(4):413-414. PubMed ID: 38547887
    [No Abstract]   [Full Text] [Related]  

  • 17. Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
    Lew TE; Bennett R; Lin VS; Whitechurch A; Handunnetti SM; Marlton P; Shen Y; Mulligan SP; Casan J; Blombery P; Tam CS; Roberts AW; Seymour JF; Thompson PA; Anderson MA
    Blood Adv; 2024 Mar; 8(6):1439-1443. PubMed ID: 38231032
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on the CAPTIVATE trial of ibrutinib plus venetoclax.
    Siddiqi T
    Clin Adv Hematol Oncol; 2023 Dec; 21(12):654-657. PubMed ID: 38039059
    [No Abstract]   [Full Text] [Related]  

  • 19. Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
    Autore F; Visentin A; Deodato M; Vitale C; Galli E; Fresa A; Fazzi R; Sanna A; Olivieri J; Scortechini I; Del Principe MI; Sportoletti P; Schiattone L; Maschio N; Facchinelli D; Marchesi F; Coscia M; Tedeschi A; Trentin L; Innocenti I; Candoni A; Busca A; Pagano L; Laurenti L
    Am J Hematol; 2024 May; 99(5):982-984. PubMed ID: 38343033
    [No Abstract]   [Full Text] [Related]  

  • 20. Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
    Avigan ZM; Joshua Richter Md
    Oncology (Williston Park); 2024 Jun; 38(6):239-241. PubMed ID: 38899981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.